

DAFTAR PUSTAKA

Abida, W. *et al.* (2019) ‘Genomic correlates of clinical outcome in advanced prostate cancer’, *Proceedings of the National Academy of Sciences*, 116(23), pp. 11428–11436. Available at: <https://doi.org/10.1073/pnas.1902651116>.

Abuzallouf, S., Dayes, I. and Lukka, H. (2004) ‘BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATURE’, *Journal of Urology*, 171(6 Part 1), pp. 2122–2127. Available at: <https://doi.org/10.1097/01.ju.0000123981.03084.06>.

Álvarez-García, V. *et al.* (2019) ‘Mechanisms of PTEN loss in cancer: It’s all about diversity’, *Seminars in Cancer Biology*, 59, pp. 66–79. Available at: <https://doi.org/10.1016/j.semcancer.2019.02.001>.

Amin Al Olama, A. *et al.* (2015) ‘Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci’, *Cancer Epidemiology, Biomarkers & Prevention*, 24(7), pp. 1121–1129. Available at: <https://doi.org/10.1158/1055-9965.EPI-14-0317>.

Antonarakis, E.S. *et al.* (2015) ‘Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer’, *JAMA oncology*, 1(5), pp. 582–591. Available at: <https://doi.org/10.1001/jamaoncol.2015.1341>.

Antonarakis, E.S. (2015) ‘Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?’, *Expert Review of Anticancer Therapy*, 15(2), pp. 143–145. Available at: <https://doi.org/10.1586/14737140.2015.999044>.

Armstrong, A.J. *et al.* (2019) ‘Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study’, *Journal of Clinical Oncology*, 37(13), pp. 1120–1129. Available at: <https://doi.org/10.1200/JCO.18.01731>.

Bhindi, B. *et al.* (2018) ‘Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma’, *Journal of Urology*, 200(3), pp. 528–534. Available at: <https://doi.org/10.1016/j.juro.2018.03.077>.

Bilke, S. *et al.* (2013) ‘Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer’, *Genome Research*, 23(11), pp. 1797–1809. Available at: <https://doi.org/10.1101/gr.151340.112>.

‘Bookshelf_NBK326791.pdf’ (no date).

Bratt, O. *et al.* (2016) ‘Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study’, *Journal of the National Cancer Institute*, 108(10), p. djw110. Available at: <https://doi.org/10.1093/jnci/djw110>.

Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. Available at: <https://doi.org/10.3322/caac.21492>.

Brierley, J., Gospodarowicz, M.K. and Wittekind, C. (eds) (2017) *TNM classification of malignant tumours*. Eighth edition. Chichester, West Sussex, UK ; Hoboken, NJ: John Wiley & Sons, Inc.

Bubley, G.J. (2001) 'Is the flare phenomenon clinically significant?', *Urology*, 58(2), pp. 5–9. Available at: [https://doi.org/10.1016/S0090-4295\(01\)01235-3](https://doi.org/10.1016/S0090-4295(01)01235-3).

Bykov, V.J.N. *et al.* (2018) 'Targeting mutant p53 for efficient cancer therapy', *Nature Reviews Cancer*, 18(2), pp. 89–102. Available at: <https://doi.org/10.1038/nrc.2017.109>.

Carter, H.B. *et al.* (2013) 'Early Detection of Prostate Cancer: AUA Guideline', *Journal of Urology*, 190(2), pp. 419–426. Available at: <https://doi.org/10.1016/j.juro.2013.04.119>.

Castro, E. and Eeles, R. (2012) 'The role of BRCA1 and BRCA2 in prostate cancer', *Asian Journal of Andrology*, 14(3), pp. 409–414. Available at: <https://doi.org/10.1038/aja.2011.150>.

Catalona, W.J. *et al.* (1994) 'Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men', *Journal of Urology*, 151(5), pp. 1283–1290. Available at: [https://doi.org/10.1016/S0022-5347\(17\)35233-3](https://doi.org/10.1016/S0022-5347(17)35233-3).

Cato, L. *et al.* (2019) 'ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer', *Cancer Cell*, 35(3), pp. 401–413.e6. Available at: <https://doi.org/10.1016/j.ccell.2019.01.008>.

Chen, R.C. *et al.* (2016) 'Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement', *Journal of Clinical Oncology*, 34(18), pp. 2182–2190. Available at: <https://doi.org/10.1200/JCO.2015.65.7759>.

Chia, S.-J. *et al.* (2000) 'Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker', *British Journal of Cancer*, 83(6), pp. 761–768. Available at: <https://doi.org/10.1054/bjoc.2000.1355>.

Chun-zhi, Z. *et al.* (2010) 'MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN', *BMC Cancer*, 10(1), p. 367. Available at: <https://doi.org/10.1186/1471-2407-10-367>.

Connor, M.J. *et al.* (2020) 'Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials', *European Urology Oncology*, 3(5), pp. 582–593. Available at: <https://doi.org/10.1016/j.euo.2020.07.004>.

Cremers, R.G. *et al.* (2014) 'Self-reported acne is not associated with prostate cancer', *Urologic Oncology: Seminars and Original Investigations*, 32(7), pp. 941–945. Available at: <https://doi.org/10.1016/j.urolonc.2014.02.019>.

D'Amico, A.V. *et al.* (no date) 'Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer', p. 7.

D'Amico, A.V. *et al.* (XXXX) 'Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer 7'.

David, C.J. and Manley, J.L. (2010) 'Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged', *Genes & Development*, 24(21), pp. 2343–2364. Available at: <https://doi.org/10.1101/gad.1973010>.

De Laere, B. *et al.* (2019) 'TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer', *Clinical Cancer Research*, 25(6), pp. 1766–1773. Available at: <https://doi.org/10.1158/1078-0432.CCR-18-1943>.

Desmond, A.D., Arnold, A.J. and Hastie, K.J. (1988) 'Subcapsular Orchiectomy under Local Anaesthesia Technique, Results and Implications', *British Journal of Urology*, 61(2), pp. 143–145. Available at: <https://doi.org/10.1111/j.1464-410X.1988.tb05063.x>.

Dienstmann, R. *et al.* (2014) 'Standardized decision support in next generation sequencing reports of somatic cancer variants', *Molecular Oncology*, 8(5), pp. 859–873. Available at: <https://doi.org/10.1016/j.molonc.2014.03.021>.

Epstein, Jonathan I *et al.* (2016) 'The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma', *Am J Surg Pathol*, 40(2), p. 9.

Epstein, Jonathan I. *et al.* (2016) 'The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System', *American Journal of Surgical Pathology*, 40(2), pp. 244–252. Available at: <https://doi.org/10.1097/PAS.0000000000000530>.

Evans, C.P. *et al.* (2016) 'The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer', *European Urology*, 70(4), pp. 675–683. Available at: <https://doi.org/10.1016/j.eururo.2016.03.017>.

Farrugia, D. *et al.* (2000) 'Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy: STILBOESTROL', *BJU International*, 85(9), pp. 1069–1073. Available at: <https://doi.org/10.1046/j.1464-410x.2000.00673.x>.

Fedchenko, N. and Reifenrath, J. (2014) 'Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review', *Diagnostic Pathology*, 9, p. 221. Available at: <https://doi.org/10.1186/s13000-014-0221-9>.

Feldman, D., Skowronski, R.J. and Peehl, D.M. (no date) 'VITAMIN D AND PROSTATE CANCER', p. 11.

Ferraldeschi, R. *et al.* (2015) 'PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate', *European Urology*, 67(4), pp. 795–802. Available at: <https://doi.org/10.1016/j.eururo.2014.10.027>.

Freedland, S.J. *et al.* (2013) 'A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy', *Cancer Prevention Research*, 6(10), pp. 1120–1127. Available at: <https://doi.org/10.1158/1940-6207.CAPR-12-0423>.

Gacci, M. *et al.* (2017) 'Meta-analysis of metabolic syndrome and prostate cancer', *Prostate Cancer and Prostatic Diseases*, 20(2), pp. 146–155. Available at: <https://doi.org/10.1038/pcan.2017.1>.

Gandaglia, G. *et al.* (2020) 'External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection', *European Urology*, 78(2), pp. 138–142. Available at: <https://doi.org/10.1016/j.eururo.2020.03.023>.

Gillessen, S. *et al.* (2020) 'Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019', *European Urology*, 77(4), pp. 508–547. Available at: <https://doi.org/10.1016/j.eururo.2020.01.012>.

Goel, S. *et al.* (2020) 'Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis', *European Urology Oncology*, 3(1), pp. 10–20. Available at: <https://doi.org/10.1016/j.euo.2019.08.001>.

Gosselaar, C. *et al.* (2008) 'The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam', *European Urology*, 54(3), pp. 581–588. Available at: <https://doi.org/10.1016/j.eururo.2008.03.104>.

Guedes, L.B. *et al.* (2017) 'Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer', *Clinical Cancer Research*, 23(16), pp. 4693–4703. Available at: <https://doi.org/10.1158/1078-0432.CCR-17-0257>.

Guo, C. *et al.* (2017) 'Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer', *Cancer Letters*, 397, pp. 133–143. Available at: <https://doi.org/10.1016/j.canlet.2017.03.022>.

Haider, A. *et al.* (2015) 'Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries', *Journal of Urology*, 193(1), pp. 80–86.

Hamid, A.A., Gray, K.P., Shaw, G., *et al.* (2019) 'Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer', *European Urology*, 76(1), pp. 89–97. Available at: <https://doi.org/10.1016/j.eururo.2018.11.045>.

Hamid, A.A., Gray, K.P., Huang, Y., *et al.* (2019) 'Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy', *European Urology Oncology*, 2(5), pp. 475–482. Available at: <https://doi.org/10.1016/j.euo.2018.09.003>.

Hamid, S., Donaldson, I.A., Hu, Y., *et al.* (2019) 'The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification', *European Urology*, 75(5), pp. 733–740. Available at: <https://doi.org/10.1016/j.eururo.2018.08.007>.

Hansen, N.L. *et al.* (2020) 'Optimising the number of cores for MAGNETIC RESONANCE IMAGING - guided targeted and systematic transperineal prostate biopsy', *BJU International*, 125(2), pp. 260–269. Available at: <https://doi.org/10.1111/bju.14865>.

Hemminki, K. (2012) 'Familial risk and familial survival in prostate cancer', *World Journal of Urology*, 30(2), pp. 143–148. Available at: <https://doi.org/10.1007/s00345-011-0801-1>.

Hernández Borrero, L.J. and El-Deiry, W.S. (2021) 'Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting', *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1876(1), p. 188556. Available at: <https://doi.org/10.1016/j.bbcan.2021.188556>.

Hernandez, D.J. *et al.* (2007) 'Contemporary Evaluation of the D'Amico Risk Classification of Prostate Cancer', *Urology*, 70(5), pp. 931–935. Available at: <https://doi.org/10.1016/j.urology.2007.08.055>.

Huggins, C. and Hodges, C.V. (2002) 'Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate', *Journal of Urology*, 168(1), pp. 9–12. Available at: [https://doi.org/10.1016/S0022-5347\(05\)64820-3](https://doi.org/10.1016/S0022-5347(05)64820-3).

Humphrey, P.A. *et al.* (2016) 'The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours', *European Urology*, 70(1), pp. 106–119. Available at: <https://doi.org/10.1016/j.eururo.2016.02.028>.

Humphrey, P.A. (2017) 'Histopathology of Prostate Cancer', *Cold Spring Harbor Perspectives in Medicine*, 7(10), p. a030411. Available at: <https://doi.org/10.1101/cshperspect.a030411>.

Huse, J.T. *et al.* (2009) 'The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo', *Genes & Development*, 23(11), pp. 1327–1337. Available at: <https://doi.org/10.1101/gad.1777409>.

Hussain, M. *et al.* (1994) 'Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report', *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 12(9), pp. 1868–1875. Available at: <https://doi.org/10.1200/JCO.1994.12.9.1868>.

Jamaspishvili, T. *et al.* (2018) 'Clinical implications of PTEN loss in prostate cancer', *Nature Reviews Urology*, 15(4), pp. 222–234. Available at: <https://doi.org/10.1038/nrurol.2018.9>.

Jamaspishvili, T. *et al.* (2020) 'Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)', *JNCI: Journal of the National Cancer Institute*, 112(11), pp. 1098–1104. Available at: <https://doi.org/10.1093/jnci/djaa032>.

Jernberg, E., Bergh, A. and Wikström, P. (2017) 'Clinical relevance of androgen receptor alterations in prostate cancer', *Endocrine Connections*, 6(8), pp. R146–R161. Available at: <https://doi.org/10.1530/EC-17-0118>.

Joseph, D. *et al.* (2020) 'Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial', *International Journal of Radiation Oncology*Biophysics*, 106(4), pp. 693–702. Available at: <https://doi.org/10.1016/j.ijrobp.2019.11.415>.

Ju-Kun, S. *et al.* (2016) 'Association Between Cd Exposure and Risk of Prostate Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis', *Medicine*, 95(6), p. e2708. Available at: <https://doi.org/10.1097/MD.0000000000002708>.

Kaku, N. *et al.* (2008) 'Characterization of Nuclear Import of the Domain-Specific Androgen Receptor in Association with the Importin α/β and Ran-Guanosine 5'-Triphosphate Systems', *Endocrinology*, 149(8), pp. 3960–3969. Available at: <https://doi.org/10.1210/en.2008-0137>.

Keyes, M. *et al.* (2017) 'American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy—A systematic literature review', *Brachytherapy*, 16(2), pp. 245–265. Available at: <https://doi.org/10.1016/j.brachy.2016.11.017>.

Khemlina, G., Ikeda, S. and Kurzrock, R. (2015) 'Molecular landscape of prostate cancer: Implications for current clinical trials', *Cancer Treatment Reviews*, 41(9), pp. 761–766. Available at: <https://doi.org/10.1016/j.ctrv.2015.07.001>.

Kim, D.K. *et al.* (2010) 'The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy', *Korean Journal of Urology*, 51(5), p. 313. Available at: <https://doi.org/10.4111/kju.2010.51.5.313>.

Kirby, M., Hirst, C. and Crawford, E.D. (2011) 'Characterising the castration-resistant prostate cancer population: a systematic review: The Epidemiology of CRPC', *International Journal of*

Clinical Practice, 65(11), pp. 1180–1192. Available at: <https://doi.org/10.1111/j.1742-1241.2011.02799.x>.

Klotz, L. *et al.* (2008) ‘The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer’, *BJU International*, 102(11), pp. 1531–1538. Available at: <https://doi.org/10.1111/j.1464-410X.2008.08183.x>.

Kote-Jarai, Z. *et al.* (2013) ‘Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression’, *Human Molecular Genetics*, 22(12), pp. 2520–2528. Available at: <https://doi.org/10.1093/hmg/ddt086>.

Krakowsky, Y. and Morgentaler, A. (2019) ‘Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth’, *European Urology Focus*, 5(1), pp. 81–89. Available at: <https://doi.org/10.1016/j.euf.2017.06.008>.

Kramer, B.S. *et al.* (2009) ‘Use of 5 α -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline’, *Journal of Urology*, 181(4), pp. 1642–1657. Available at: <https://doi.org/10.1016/j.juro.2009.01.071>.

Krohn, Antje *et al.* (2012) ‘Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer’, *The American Journal of Pathology*, 181(2), pp. 401–412. Available at: <https://doi.org/10.1016/j.ajpath.2012.04.026>.

Krohn, A. *et al.* (2012) ‘Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer’, *Am J Pathol*, 181, pp. 401–412. Available at: <https://doi.org/10.1016/j.ajpath.2012.04.026>.

Ku, S.-Y., Gleave, M.E. and Beltran, H. (2019) ‘Towards precision oncology in advanced prostate cancer’, *Nature Reviews Urology*, 16(11), pp. 645–654. Available at: <https://doi.org/10.1038/s41585-019-0237-8>.

Li, Heng *et al.* (2021) ‘Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy’, *European Urology*, 79(6), pp. 879–886. Available at: <https://doi.org/10.1016/j.eururo.2021.01.037>.

Li, Y. *et al.* (2022) ‘A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer’, *Acta Pharmaceutica Sinica B*, 12(11), pp. 4165–4179. Available at: <https://doi.org/10.1016/j.apsb.2022.05.003>.

Lian, W.-Q. *et al.* (2015) ‘Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies’, *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, 21, pp. 1895–1903. Available at: <https://doi.org/10.12659/MSM.893579>.

Lin, Y.-S. *et al.* (2013) 'Increased Risk of Cancer Mortality Associated with Cadmium Exposures in Older Americans with Low Zinc Intake', *Journal of Toxicology and Environmental Health, Part A*, 76(1), pp. 1–15. Available at: <https://doi.org/10.1080/15287394.2012.722185>.

Lippman, S.M. *et al.* (2009) 'Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)', *JAMA*, 301(1), p. 39. Available at: <https://doi.org/10.1001/jama.2008.864>.

Litman, H.J. *et al.* (2006) 'Serum Androgen Levels in Black, Hispanic, and White Men', *The Journal of Clinical Endocrinology & Metabolism*, 91(11), pp. 4326–4334. Available at: <https://doi.org/10.1210/jc.2006-0037>.

Loriot, Y. *et al.* (2015) 'Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer', *European Journal of Cancer*, 51(14), pp. 1946–1952. Available at: <https://doi.org/10.1016/j.ejca.2015.06.128>.

Lowder, D. *et al.* (2022) 'Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics', *Cancer letters*, 531, pp. 71–82.

Luo, J. (2016) 'Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer', *Asian Journal of Andrology*, 18(4), p. 580. Available at: <https://doi.org/10.4103/1008-682X.178490>.

Mannaerts, C.K. *et al.* (2018) 'Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy', *European Urology Oncology*, 1(2), pp. 109–117. Available at: <https://doi.org/10.1016/j.euo.2018.02.010>.

Mao, X. *et al.* (2010) 'Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis', *Cancer Research*, 70(13), pp. 5207–5212. Available at: <https://doi.org/10.1158/0008-5472.CAN-09-4074>.

Marchetti, B. *et al.* (1989) 'Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Restoration of Age-Associated Decline of Thymus Weight, Thymic LHRH Receptors, and Thymocyte Proliferative Capacity', *Endocrinology*, 125(2), pp. 1037–1045. Available at: <https://doi.org/10.1210/endo-125-2-1037>.

Mateo, J. *et al.* (2020) 'Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial', *The Lancet. Oncology*, 21(1), pp. 162–174. Available at: [https://doi.org/10.1016/S1470-2045\(19\)30684-9](https://doi.org/10.1016/S1470-2045(19)30684-9).

McCormick, D.L. *et al.* (2010) 'Null Activity of Selenium and Vitamin E as Cancer Chemopreventive Agents in the Rat Prostate', *Cancer Prevention Research*, 3(3), pp. 381–392. Available at: <https://doi.org/10.1158/1940-6207.CAPR-09-0176>.

Moch, H. *et al.* (2016) 'The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours', *European Urology*, 70(1), pp. 93–105. Available at: <https://doi.org/10.1016/j.eururo.2016.02.029>.

Mochtar, C.A. *et al.* (2018) 'Prostate cancer detection rate in Indonesian men', *Asian Journal of Surgery*, 41(2), pp. 163–169. Available at: <https://doi.org/10.1016/j.asjsur.2017.01.001>.

Moffat, L.E.F. (1990) 'Comparison of Zoladex, Diethylstilbestrol and Cyproterone Acetate Treatment in Advanced Prostate Cancer', *European Urology*, 18(3), pp. 26–27. Available at: <https://doi.org/10.1159/000463975>.

Morote, J. *et al.* (2009) 'Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy', *BJU International*, 103(3), pp. 332–335. Available at: <https://doi.org/10.1111/j.1464-410X.2008.08062.x>.

Mottet, N. *et al.* (2021a) 'EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent', *European Urology*, 79(2), pp. 243–262. Available at: <https://doi.org/10.1016/j.eururo.2020.09.042>.

Mottet, N. *et al.* (2021b) 'EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent', *European Urology*, 79(2), pp. 243–262. Available at: <https://doi.org/10.1016/j.eururo.2020.09.042>.

Mottet, N. *et al.* (2021c) 'EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent', *European Urology*, 79(2), pp. 243–262. Available at: <https://doi.org/10.1016/j.eururo.2020.09.042>.

Mustafa, M. *et al.* (XXXX) 'Prostate Cancer: Pathophysiology, Diagnosis, and Prognosis'.

Mustafa, M. *et al.* (no date) 'Prostate Cancer: Pathophysiology, Diagnosis, and Prognosis', *Prostate Cancer*, p. 8.

Nava Rodrigues, D. *et al.* (2019) 'RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer', *Clinical Cancer Research*, 25(2), pp. 687–697. Available at: <https://doi.org/10.1158/1078-0432.CCR-18-2068>.

Niraula, S., Le, L.W. and Tannock, I.F. (2013) 'Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials', *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 31(16), pp. 2029–2036. Available at: <https://doi.org/10.1200/JCO.2012.46.5492>.

Nyquist, M.D. *et al.* (2020) 'Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress', *Cell Reports*, 31(8), p. 107669. Available at: <https://doi.org/10.1016/j.celrep.2020.107669>.

Okotie, O.T. *et al.* (2007) 'Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only', *Urology*, 70(6), pp. 1117–1120. Available at: <https://doi.org/10.1016/j.urology.2007.07.019>.

Olov Hedlund, P. *et al.* (2008) 'Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5', *Scandinavian Journal of Urology and Nephrology*, 42(3), pp. 220–229. Available at: <https://doi.org/10.1080/00365590801943274>.

Organisation mondiale de la santé and Centre international de recherche sur le cancer (eds) (2016) *WHO classification of tumours of the urinary system and male genital organs*. Lyon: International agency for research on cancer (World health organization classification of tumours, 8).

Ouyang, W. *et al.* (2021) 'Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy', *Biomarker Research*, 9(1), p. 23. Available at: <https://doi.org/10.1186/s40364-021-00276-x>.

Page, E.C. *et al.* (2019) 'Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers', *European Urology*, 76(6), pp. 831–842. Available at: <https://doi.org/10.1016/j.eururo.2019.08.019>.

Parikesit, D. *et al.* (2016a) 'The impact of obesity towards prostate diseases', *Prostate International*, 4(1), pp. 1–6. Available at: <https://doi.org/10.1016/j.pnrl.2015.08.001>.

Parikesit, D. *et al.* (2016b) 'The impact of obesity towards prostate diseases', *Prostate International*, 4(1), pp. 1–6. Available at: <https://doi.org/10.1016/j.pnrl.2015.08.001>.

Perdana, N.R. *et al.* (2016) 'The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review', *Acta Medica Indonesiana*, 48(3), pp. 228–238.

Perdomo, H.A.G., Zapata-Copete, J.A. and Sanchez, A. (2018) 'Molecular alterations associated with prostate cancer', *Central European Journal of Urology*, 71(2), pp. 168–176. Available at: <https://doi.org/10.5173/ceju.2018.1583>.

Perletti, G. *et al.* (2017) 'The association between prostatitis and prostate cancer. Systematic review and meta-analysis', *Archivio Italiano di Urologia e Andrologia*, 89(4), pp. 259–265. Available at: <https://doi.org/10.4081/aiua.2017.4.259>.

Pickles, T. *et al.* (2012) 'Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?: *INCOMPLETE TESTOSTERONE SUPPRESSION*', *BJU International*, 110(11b), pp. E500–E507. Available at: <https://doi.org/10.1111/j.1464-410X.2012.11190.x>.

Preston, M.A. *et al.* (2014) 'Metformin Use and Prostate Cancer Risk', *European Urology*, 66(6), pp. 1012–1020. Available at: <https://doi.org/10.1016/j.eururo.2014.04.027>.

Qu, Y. *et al.* (2015) 'Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer', *Scientific Reports*, 5(1), p. 7654. Available at: <https://doi.org/10.1038/srep07654>.

Quinn, E.A. *et al.* (2019) 'From uncertainty to pathogenicity: clinical and functional interrogation of a rare *TP53* in-frame deletion', *Molecular Case Studies*, 5(4), p. a003921. Available at: <https://doi.org/10.1101/mcs.a003921>.

Randazzo, M. *et al.* (2016) 'A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: Results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau', *BJU International*, 117(4), pp. 576–583.

Rawla, P. (2019) 'Epidemiology of Prostate Cancer', *World Journal of Oncology*, 10(2), pp. 63–89. Available at: <https://doi.org/10.14740/wjon1191>.

Richie, J.P. *et al.* (1993) 'Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination', *Urology*, 42(4), pp. 365–374. Available at: [https://doi.org/10.1016/0090-4295\(93\)90359-I](https://doi.org/10.1016/0090-4295(93)90359-I).

Richstone, L. *et al.* (2008) 'Radical prostatectomy in men aged ≥ 70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram', *BJU International*, 101(5), pp. 541–546. Available at: <https://doi.org/10.1111/j.1464-410X.2007.07410.x>.

Rider, J.R. *et al.* (2016) 'Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up', *European Urology*, 70(6), pp. 974–982. Available at: <https://doi.org/10.1016/j.eururo.2016.03.027>.

Robinson, D. *et al.* (2015) 'Integrative Clinical Genomics of Advanced Prostate Cancer', *Cell*, 161(5), pp. 1215–1228. Available at: <https://doi.org/10.1016/j.cell.2015.05.001>.

Rodda, S. *et al.* (2017) 'ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer', *International Journal of Radiation Oncology*Biophysics*, 98(2), pp. 286–295. Available at: <https://doi.org/10.1016/j.ijrobp.2017.01.008>.

Rodriguez-Bravo, V. *et al.* (2018) 'Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import', *Cell*, 174(5), pp. 1200–1215.e20. Available at: <https://doi.org/10.1016/j.cell.2018.07.015>.

Russo, G.I. *et al.* (2020) 'Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis', *The Aging Male*, 23(2), pp. 132–138. Available at: <https://doi.org/10.1080/13685538.2018.1455178>.

Sachdeva, K. *et al.* (2011) 'Use of Ethnicity-Specific Sequence Tag Site Markers for Y Chromosome Microdeletion Studies', *Genetic Testing and Molecular Biomarkers*, 15(6), pp. 451–459. Available at: <https://doi.org/10.1089/gtmb.2010.0159>.

Safriadi, F. and Novesar, A.R. (2021) 'Five-Year Profiles of Prostate Cancer Patients in A Tertiary Hospital in Indonesia', *Majalah Kedokteran Bandung*, 53(2). Available at: <https://doi.org/10.15395/mkb.v53n2.2212>.

Saylor, P.J. *et al.* (2017) ‘Branched Chain RNA In Situ&/em> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer’, *Clinical Cancer Research*, 23(2), p. 363 LP – 369. Available at: <https://doi.org/10.1158/1078-0432.CCR-16-0237>.

Seidenfeld, J. *et al.* (2000) ‘Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer: A Systematic Review and Meta-Analysis’, *Annals of Internal Medicine*, 132(7), p. 566. Available at: <https://doi.org/10.7326/0003-4819-132-7-200004040-00009>.

Sharifi, N. and Auchus, R.J. (2012) ‘Steroid biosynthesis and prostate cancer’, *Steroids*, 77(7), pp. 719–726. Available at: <https://doi.org/10.1016/j.steroids.2012.03.015>.

Sharma, A. *et al.* (2010) ‘The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression’, *Journal of Clinical Investigation*, 120(12), pp. 4478–4492. Available at: <https://doi.org/10.1172/JCI44239>.

Shore, N.D. (2013) ‘Experience with degarelix in the treatment of prostate cancer’, *Therapeutic Advances in Urology*, 5(1), pp. 11–24. Available at: <https://doi.org/10.1177/1756287212461048>.

Silva, F.C. da *et al.* (2014) ‘Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Urooncological Group’, *European Urology*, 66(2), pp. 232–239. Available at: <https://doi.org/10.1016/j.eururo.2013.03.055>.

Sobhani, N. *et al.* (2021) ‘AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption’, *International Journal of Molecular Sciences*, 22(11), p. 5515. Available at: <https://doi.org/10.3390/ijms22115515>.

Soerohardjo, I. *et al.* (2020) ‘Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study’, *Annals of Medicine and Surgery*, 60, pp. 549–554. Available at: <https://doi.org/10.1016/j.amsu.2020.11.017>.

Stapleton, A.M. *et al.* (1998) ‘Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery’, *Cancer*, 82(1), pp. 168–175. Available at: [https://doi.org/10.1002/\(sici\)1097-0142\(19980101\)82:1<168::aid-cnrcr21>3.0.co;2-#](https://doi.org/10.1002/(sici)1097-0142(19980101)82:1<168::aid-cnrcr21>3.0.co;2-#).

Stewart, R.W. *et al.* (2017) ‘Screening for prostate cancer’, *Seminars in Oncology*, 44(1), pp. 47–56. Available at: <https://doi.org/10.1053/j.seminoncol.2017.02.001>.

Sydes, M.R. *et al.* (2018) ‘Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol’, *Annals of Oncology*, 29(5), pp. 1235–1248. Available at: <https://doi.org/10.1093/annonc/mdy072>.

Taksler, G.B., Keating, N.L. and Cutler, D.M. (2012) ‘Explaining racial differences in prostate cancer mortality: Prostate Cancer Mortality Differences’, *Cancer*, 118(17), pp. 4280–4289. Available at: <https://doi.org/10.1002/cnrcr.27379>.

Tamada, S. *et al.* (2018) 'Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer', *Oncotarget*, 9(97), pp. 36966–36974.

Tanaka, T., Watanabe, M. and Yamashita, K. (2018) 'Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer', *Oncotarget*, 9(22), pp. 16234–16247. Available at: <https://doi.org/10.18632/oncotarget.24611>.

Taylor, B.S. *et al.* (2010) 'Integrative Genomic Profiling of Human Prostate Cancer', *Cancer Cell*, 18(1), pp. 11–22. Available at: <https://doi.org/10.1016/j.ccr.2010.05.026>.

Theodorescu, D. *et al.* (1997) 'p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate', *The Journal of urology*, 158(1), pp. 131–137. Available at: <https://doi.org/10.1097/00005392-199707000-00040>.

Tian, L. *et al.* (2013) 'Four MicroRNAs Promote Prostate Cell Proliferation with Regulation of PTEN and Its Downstream Signals In Vitro', *PLoS ONE*. Edited by S. Pfeffer, 8(9), p. e75885. Available at: <https://doi.org/10.1371/journal.pone.0075885>.

Tosoian, J.J. *et al.* (2017) 'Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy', *European Urology*, 71(5), pp. 697–700. Available at: <https://doi.org/10.1016/j.eururo.2016.07.026>.

Umbas, R. *et al.* (2015) 'Urologic cancer in Indonesia', *Japanese Journal of Clinical Oncology*, 45(8), pp. 708–712. Available at: <https://doi.org/10.1093/jjco/hyv066>.

Usoro, A.J. *et al.* (2015) 'Serum Testosterone, 17 β -Estradiol and PSA Levels in Subjects with Prostate Disorders', *Indian journal of clinical biochemistry: IJCB*, 30(1), pp. 59–65. Available at: <https://doi.org/10.1007/s12291-013-0411-3>.

Van den Bergh, L. *et al.* (2015) 'Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement', *Urologic Oncology: Seminars and Original Investigations*, 33(3), p. 109.e23-109.e31. Available at: <https://doi.org/10.1016/j.urolonc.2014.11.008>.

Vidal, A.C. *et al.* (2014) 'Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study', *Cancer Epidemiology, Biomarkers & Prevention*, 23(12), pp. 2936–2942. Available at: <https://doi.org/10.1158/1055-9965.EPI-14-0795>.

Watson, A.P. *et al.* (2020) 'Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in TP53, PTEN and RB1 on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer', *American Journal of Clinical and Experimental Urology*, 8(4), pp. 106–115.

Watson, P.A., Arora, V.K. and Sawyers, C.L. (2015) 'Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer', *Nature Reviews Cancer*, 15(12), pp. 701–711. Available at: <https://doi.org/10.1038/nrc4016>.

Watts, E.L. *et al.* (2018) 'Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies', *European Urology*, 74(5), pp. 585–594. Available at: <https://doi.org/10.1016/j.eururo.2018.07.024>.

Weiner, A.B. *et al.* (2021) 'Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis', *Cancer*, 127(16), pp. 2895–2904. Available at: <https://doi.org/10.1002/cncr.33584>.

Wilt, T.J. *et al.* (2020) 'Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)', *European Urology*, 77(6), pp. 713–724. Available at: <https://doi.org/10.1016/j.eururo.2020.02.009>.

de Wit, R. *et al.* (2019) 'Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer', *New England Journal of Medicine*, 381(26), pp. 2506–2518. Available at: <https://doi.org/10.1056/NEJMoa1911206>.

Yadav, S. *et al.* (2019) 'Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome', *JCO Precision Oncology*, (3), pp. 1–12. Available at: <https://doi.org/10.1200/PO.19.00067>.

Yadav, S.S. *et al.* (2015a) 'Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment', *Urologic Oncology: Seminars and Original Investigations*, 33(6), p. 267.e1-267.e13. Available at: <https://doi.org/10.1016/j.urolonc.2015.02.009>.

Yadav, S.S. *et al.* (2015b) 'Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment', *Urologic Oncology: Seminars and Original Investigations*, 33(6), p. 267.e1-267.e13. Available at: <https://doi.org/10.1016/j.urolonc.2015.02.009>.

Yang, F.-Q. *et al.* (2015) 'Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA-21', *Molecular Medicine Reports*, 11(2), pp. 1085–1092. Available at: <https://doi.org/10.3892/mmr.2014.2813>.

YuPeng, L. *et al.* (2015) 'Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies', *Cancer Epidemiology, Biomarkers & Prevention*, 24(7), pp. 1086–1093. Available at: <https://doi.org/10.1158/1055-9965.EPI-14-1329>.

Zeigler-Johnson, C.M. *et al.* (2008) 'Evaluation of prostate cancer characteristics in four populations worldwide', *The Canadian Journal of Urology*, 15(3), pp. 4056–4064.

Zhang, J.-Y. *et al.* (2022) 'Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer', *Asian Journal of Andrology*, 24(1), p. 50. Available at: https://doi.org/10.4103/aja.aja_39_21.

Zhao, J. *et al.* (2014) ‘Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies’, *PLoS ONE*. Edited by N. Kyprianou, 9(9), p. e107516. Available at: <https://doi.org/10.1371/journal.pone.0107516>.

Zhao, Y.-X. *et al.* (2021) ‘Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer’, *Clinical Medicine Insights. Oncology*, 15, p. 11795549211049750.

Zhau, H.E. *et al.* (1995) ‘Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations’, *Urologic Oncology: Seminars and Original Investigations*, 1(2), pp. 51–63. Available at: [https://doi.org/10.1016/1078-1439\(95\)00009-7](https://doi.org/10.1016/1078-1439(95)00009-7).

Zhou, C.K. *et al.* (2016) ‘Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group’, *International Journal of Cancer*, 138(6), pp. 1388–1400. Available at: <https://doi.org/10.1002/ijc.29894>.

Zhou, Y., Bolton, E.C. and Jones, J.O. (2015) ‘Androgens and androgen receptor signaling in prostate tumorigenesis’, *Journal of Molecular Endocrinology*, 54(1), pp. R15–R29. Available at: <https://doi.org/10.1530/JME-14-0203>.

Zhu, Y. *et al.* (2021) ‘Epidemiology and genomics of prostate cancer in Asian men’, *Nature Reviews Urology*, 18(5), pp. 282–301. Available at: <https://doi.org/10.1038/s41585-021-00442-8>.